{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:30:08Z","timestamp":1786609808784,"version":"build-2736575974"},"reference-count":161,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Graves\u2019 disease (GD) is an autoimmune disorder characterized by the production of stimulatory autoantibodies against the thyrotropin receptor, leading to hyperthyroidism and diffuse goiter. The most frequent extrathyroidal manifestation is Graves\u2019 ophthalmopathy (GO), also known as thyroid eye disease (TED), which is responsible for significant morbidity due to orbital inflammation, tissue remodeling, and visual impairment. In recent years, increasing evidence has demonstrated that cytokines play a central role in both GD and TED, orchestrating immune cell activation, autoantibody production, fibroblast stimulation, and tissue remodeling. The evolving understanding of cytokine networks has reshaped disease models and paved the way for targeted therapies that interfere with specific immune pathways. We review the immunepathogenesis of GD and TED, the role of cytokine networks, and the available cytokine-targeted therapies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1800029","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:00:43Z","timestamp":1786608043000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cytokines and drugs targeting cytokines in Graves\u2019 disease and thyroid eye disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Silvia Martina","family":"Ferrari","sequence":"first","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Elia","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ragusa","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Balestri","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Botrini","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Mazzi","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Baglini","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia","family":"Rugani","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Del Carlo","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Rizzi","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Cimbalo","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Virili","sequence":"additional","affiliation":[{"name":"Department of Medico-Surgical Sciences and Biotechnologies, Endocrinology Section, \u201cSapienza\u201d University of Rome","place":["Latina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enke","family":"Baldini","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, \u201cSapienza\u201d University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Varricchi","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences (DiSMeT), University of Naples Federico II","place":["Naples, Italy"]},{"name":"Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II","place":["Naples, Italy"]},{"name":"World Allergy Organization Center of Excellence, University of Naples, Federico II","place":["Naples, Italy"]},{"name":"Institute of Experimental Endocrinology and Oncology (IEOS), National Research Council (CNR)","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poupak","family":"Fallahi","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.10.016","article-title":"Autoimmune thyroid disorders","volume":"14","author":"Antonelli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/medsci13020043","article-title":"A scoping review on the prevalence of Hashimoto's thyroiditis and the possible associated factors","volume":"13","author":"Vargas-Uricoechea","year":"2025","journal-title":"Med Sci (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.101366","article-title":"Novel therapies for thyroid autoimmune diseases: An update","volume":"34","author":"Ferrari","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5128","article-title":"Diagnosis and management of thyrotoxicosis","volume":"349","author":"Vaidya","year":"2014","journal-title":"BMJ"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/er.2013-1055","article-title":"Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity","volume":"35","author":"Sm","year":"2014","journal-title":"Endocr Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001052","article-title":"Thyrotropin receptor antibodies-an overview","volume":"34","author":"Kotwal","year":"2018","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1055\/a-0723-9023","article-title":"Thyrotropin receptor blocking antibodies","volume":"50","author":"Diana","year":"2018","journal-title":"Horm Metab Res Horm Stoffwechselforschung Horm Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101388","article-title":"Graves\u2019 disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy","volume":"34","author":"Antonelli","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.5103","article-title":"Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease","volume":"133","author":"Stein","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/tjo.tjo_51_21","article-title":"Thyroid eye disease: From pathogenesis to targeted therapies","volume":"12","author":"Yoon","year":"2022","journal-title":"Taiwan J Ophthalmol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.17.5.911","article-title":"CD4+ T cells and the Th1\/Th2 imbalance are implicated in the pathogenesis of Graves\u2019 ophthalmopathy","volume":"17","author":"Xia","year":"2006","journal-title":"Int J Mol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.2.6333","article-title":"Relationship between disease duration and predominant orbital T cell subset in Graves\u2019 ophthalmopathy","volume":"85","author":"Aniszewski","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1677\/JOE-07-0240","article-title":"Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes","volume":"195","author":"Crescioli","year":"2007","journal-title":"J Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01708.x","article-title":"TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves\u2019 ophthalmopathy patients","volume":"58","author":"Wakelkamp","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61030500","article-title":"Graves\u2019 disease: Is it time for targeted therapy? A narrative review","volume":"61","author":"Viola","year":"2025","journal-title":"Med (Mex)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70647","article-title":"Monoclonal antibodies to thyrotropin receptor with thyroid-stimulating activity activate the NF-\u03baB pathway to induce chemokine expression","volume":"29","author":"Yang","year":"2025","journal-title":"J Cell Mol Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2019.100196","article-title":"Chemokines in hyperthyroidism","volume":"16","author":"Ferrari","year":"2019","journal-title":"J Clin Transl Endocrinol"},{"key":"B19","first-page":"B5177","article-title":"Regulatory B and T cell responses in patients with autoimmune thyroid disease and healthy controls","volume":"63","author":"Kristensen","year":"2016","journal-title":"Dan Med J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.25.022106.141557","article-title":"IL-17 family cytokines and the expanding diversity of effector T cell lineages","volume":"25","author":"Weaver","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.ej13-0484","article-title":"Serum interleukin-23 (IL-23) is increased in Hashimoto\u2019s thyroiditis","volume":"61","author":"Ruggeri","year":"2014","journal-title":"Endocr J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2013.10.001","article-title":"Th17 cell plays a role in the pathogenesis of Hashimoto\u2019s thyroiditis in patients","volume":"149","author":"Li","year":"2013","journal-title":"Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.959477","article-title":"The changes in peripheral blood Th17 and Treg ratios in Hashimoto\u2019s thyroiditis are accompanied by differential PD-1\/PD-L1 expression","volume":"13","author":"Fang","year":"2022","journal-title":"Front Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf655","article-title":"Secukinumab in moderate-to-severe Graves\u2019 orbitopathy: A randomized, double-blind, placebo-controlled, multicenter study","volume":"111","author":"Wolf","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2017.04.012","article-title":"BREG cells in Hashimoto's thyroiditis isolated or associated to further organ-specific autoimmune diseases","volume":"184","author":"Santaguida","year":"2017","journal-title":"Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184413","article-title":"Immune and inflammatory cells in thyroid cancer microenvironment","volume":"20","author":"Ferrari","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2023.101773","article-title":"Chemokines in thyroid autoimmunity","volume":"37","author":"Ferrari","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.754386","article-title":"Precision medicine in Graves\u2019 disease and ophthalmopathy","volume":"12","author":"Elia","year":"2021","journal-title":"Front Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14155528","article-title":"Redefining treatment paradigms in thyroid eye disease: Current and future therapeutic strategies","volume":"14","author":"Ciarmatori","year":"2025","journal-title":"J Clin Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01197","article-title":"Cytokine secretion and pyroptosis of thyroid follicular cells mediated by enhanced NLRP3, NLRP1, NLRC4, and AIM2 inflammasomes are associated with autoimmune thyroiditis","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cimb46040220","article-title":"Inflammasome molecular insights in autoimmune diseases","volume":"46","author":"Neam\u021bu","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.humimm.2010.01.023","article-title":"The association of interleukin-1alpha and interleukin-1beta polymorphisms with the risk of Graves\u2019 disease in a case-control study and meta-analysis","volume":"71","author":"Liu","year":"2010","journal-title":"Hum Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1245","article-title":"Divergent expression of IL-1 receptor antagonists in CD34\u207a fibrocytes and orbital fibroblasts in thyroid-associated ophthalmopathy: contribution of fibrocytes to orbital inflammation","volume":"98","author":"Li","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/stresses4010004","article-title":"Orbital inflammation in thyroid eye disease: Stress responses and their implications","volume":"4","author":"Aoun","year":"2024","journal-title":"Stresses"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191247","article-title":"Effects of interleukin-2 in immunostimulation and immunosuppression","volume":"217","author":"Pol","year":"2020","journal-title":"J Exp Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/ar565","article-title":"The paradigm of IL-6: from basic science to medicine","volume":"4","author":"Naka","year":"2002","journal-title":"Arthritis Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2025.1544436","article-title":"The role of IL-6 in thyroid eye disease: an update on emerging treatments","volume":"5","author":"Murdock","year":"2025","journal-title":"Front Ophthalmol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028456","article-title":"Interleukin (IL-6) immunotherapy","volume":"10","author":"Tanaka","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2586216","article-title":"Role of interleukin 17 and T helper cells 17 cells as a new immune target and signalling in the pathogenesis and treatment of autoimmune thyroid diseases","volume":"57","author":"He","year":"2025","journal-title":"Ann Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2249.2007.03356.x","article-title":"The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease","volume":"148","author":"Afzali","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.advms.2021.07.002","article-title":"Clinical relevance of estimating circulating interleukin-17 and interleukin-23 during methylprednisolone therapy in Graves\u2019 orbitopathy: A preliminary study","volume":"66","author":"Ko\u015bciuszko","year":"2021","journal-title":"Adv Med Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2528046","article-title":"Cytokines in thyroid-associated ophthalmopathy","volume":"2022","author":"Zhang","year":"2022","journal-title":"J Immunol Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.654473","article-title":"Cytokines as targets of novel therapies for Graves\u2019 ophthalmopathy","volume":"12","author":"Fallahi","year":"2021","journal-title":"Front Endocrinol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80165-x","article-title":"Chemokines: a new classification system and their role in immunity","volume":"12","author":"Zlotnik","year":"2000","journal-title":"Immunity"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.62.5.554","article-title":"The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer","volume":"62","author":"Arenberg","year":"1997","journal-title":"J Leukoc Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345149","article-title":"Role for interferon-gamma inducible chemokines in endocrine autoimmunity: an expanding field","volume":"26","author":"Rotondi","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02137","article-title":"Increased serum CXCL10 in Graves\u2019 disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process","volume":"154","author":"Antonelli","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0002-9440(10)64171-5","article-title":"Expression of IP-10\/CXCL10 and MIG\/CXCL9 in the thyroid and increased levels of IP-10\/CXCL10 in the serum of patients with recent-onset Graves\u2019 disease","volume":"161","author":"Romagnani","year":"2002","journal-title":"Am J Pathol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01824.x","article-title":"Detection and localization of chemokine gene expression in autoimmune thyroid disease","volume":"59","author":"Kemp","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01847","article-title":"Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis","volume":"152","author":"Antonelli","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.10.7953","article-title":"Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes","volume":"86","author":"Garc\u00eda-L\u00f3pez","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B53","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1172\/JCI9775","article-title":"Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity","volume":"107","author":"Romagnani","year":"2001","journal-title":"J Clin Invest"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01778.x","article-title":"Graves\u2019 disease is associated with an altered CXCR3 and CCR5 expression in thyroid-derived compared to peripheral blood lymphocytes","volume":"127","author":"Aust","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0977","article-title":"High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism","volume":"89","author":"Antonelli","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.05.004","article-title":"Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves\u2019 disease and ophthalmopathy","volume":"18","author":"Ferrari","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02447.x","article-title":"Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves\u2019 disease, and modulation by methimazole therapy","volume":"64","author":"Antonelli","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0019","article-title":"Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves\u2019 disease","volume":"156","author":"Inukai","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1571","article-title":"Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves\u2019 disease or toxic nodular goiter","volume":"92","author":"Antonelli","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2009.0222","article-title":"A CXC motif ligand 10 polymorphism as a marker to predict severity of Graves\u2019 disease","volume":"20","author":"Br\u00fcck","year":"2010","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2009.0179","article-title":"Serum chemokine (C-X-C motif) ligand 10 levels are elevated in patients with Graves\u2019 disease in long-term remission","volume":"20","author":"Sakai","year":"2010","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1689","article-title":"Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves\u2019 ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"91","author":"Antonelli","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1316352","article-title":"Circulating CXCL9 and CXCL10 as markers of activity of Graves\u2019 orbitopathy during treatment with corticosteroids and teleradiotherapy","volume":"44","author":"Mysliwiec","year":"2012","journal-title":"Horm Metab Res Horm Stoffwechselforschung Horm Metab"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1210\/jc.2013-3919","article-title":"A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves\u2019 ophthalmopathy","volume":"99","author":"Zhu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(00)01812-3","article-title":"RANTES: a versatile and controversial chemokine","volume":"22","author":"Appay","year":"2001","journal-title":"Trends Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3109\/10428194.2011.605190","article-title":"The role of CD40\/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment","volume":"53","author":"Aldinucci","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2020.1786132","article-title":"Altered expression of CXCL13 and its chemokine receptor CXCR5 on B lymphocytes during active Graves\u2019 orbitopathy","volume":"46","author":"Wan","year":"2021","journal-title":"Curr Eye Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1177\/2042018820958335","article-title":"Glucocorticoids in Graves\u2019 orbitopathy: mechanisms of action and clinical application","volume":"11","author":"L\u00e4ngericht","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002573","article-title":"Efficiency and safety of tocilizumab for the treatment of thyroid eye disease: a systematic review","volume":"40","author":"Duarte","year":"2024","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae711","article-title":"The efficacy and safety of intravenous tocilizumab to treat Graves\u2019 ophthalmopathy: a systematic review and single-arm meta-analysis","volume":"110","author":"Sun","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0929-z","article-title":"Sarilumab: a review in moderate to severe rheumatoid arthritis","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.4039","article-title":"Scientific abstract. AB1315 Sarilumab in patients with refractory Graves\u2019 orbitopathy. Effectiveness and safety in a series of cases in clinical practice","volume":"81","author":"Moreira Navarrete","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B74","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.1038\/s41598-026-35682-4","article-title":"Sarilumab in the management of Graves orbitopathy with low clinical activity scores","volume":"16","author":"P\u00e9rez-Moreiras","year":"2026","journal-title":"Sci Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01380-2","article-title":"Satralizumab: first approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"B76","article-title":"ENSPRYNG (satralizumab-mwge) injection","volume-title":"Highlights of Prescribing Information","year":""},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-025-01255-3","article-title":"Targeting IL-6 receptor signaling with satralizumab in thyroid eye disease: design of the phase 3 SatraGO-1 and SatraGO-2 trials","volume":"14","author":"Ezra","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.5114\/ceji.2019.92803","article-title":"Etanercept in the treatment of Graves' ophthalmopathy with primary hypothyroidism and rheumatoid arthritis","volume":"44","author":"Boskovic","year":"2019","journal-title":"Cent Eur J Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701768","article-title":"The effect of etanercept on Graves\u2019 ophthalmopathy: a pilot study","volume":"19","author":"Paridaens","year":"2005","journal-title":"Eye"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1080\/01676830590912562","article-title":"Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy","volume":"24","author":"Durrani","year":"2005","journal-title":"Orbit"},{"key":"B81","article-title":"Monoclonal anti-TNFalpha antibody (infliximab) in the treatment of patient with thyroid associated ophthalmopathy","volume":"109","author":"Komorowski","year":"2007","journal-title":"Klin Oczna"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000211","article-title":"Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease","volume":"30","author":"Ayabe","year":"2014","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.09.007","article-title":"Treatment of Graves\u2019 disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies","volume":"130","author":"El Fassi","year":"2009","journal-title":"Clin Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0084","article-title":"Rituximab in relapsing Graves\u2019 disease, a phase II study","volume":"159","author":"Heemstra","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab763","article-title":"Adjuvant Rituximab-Exploratory Trial in Young People With Graves Disease","volume":"107","author":"Cheetham","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2388","article-title":"B lymphocyte depletion with the monoclonal antibody rituximab in Graves\u2019 disease: a controlled pilot study","volume":"92","author":"El Fassi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02140","article-title":"The rationale for B lymphocyte depletion in Graves\u2019 disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option","volume":"154","author":"El Fassi","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12141","article-title":"The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves\u2019 orbitopathy","volume":"79","author":"Mitchell","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2018.1453078","article-title":"Low-dose rituximab for active moderate to severe Graves\u2019 orbitopathy resistant to conventional treatment","volume":"27","author":"Du Pasquier-Fediaevsky","year":"2019","journal-title":"Ocul Immunol Inflammation"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13970","article-title":"Early low-dose rituximab for active thyroid eye disease: an effective and well-tolerated treatment","volume":"91","author":"Insull","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2111","article-title":"Efficacy and safety of rituximab for the treatment of Graves\u2019 orbitopathy: a meta-analysis of randomized controlled trials","volume":"38","author":"Shen","year":"2018","journal-title":"Pharmacotherapy"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3275\/7411","article-title":"Systemic adverse events following rituximab therapy in patients with Graves\u2019 disease","volume":"34","author":"El Fassi","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.3974","article-title":"Tofacitinib for refractory thyroid eye disease","volume":"143","author":"Ghahvehchian","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acc.2016.04.001","article-title":"Therapeutic drug monitoring of mycophenolic acid","volume":"76","author":"Dasgupta","year":"2016","journal-title":"Adv Clin Chem"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2007.00136.x","article-title":"Mycophenolate mofetil","volume":"20","author":"Zwerner","year":"2007","journal-title":"Dermatol Ther"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1140196","article-title":"Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients","volume":"14","author":"Li","year":"2023","journal-title":"Front Endocrinol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S305717","article-title":"Real-world efficacy and safety of mycophenolate mofetil in active moderate-to-sight-threatening thyroid eye disease","volume":"15","author":"Quah Qin Xian","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1177\/20420188251383022","article-title":"The role of mycophenolate mofetil in the therapy of thyroid eye disease","volume":"16","author":"Witowska","year":"2025","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02748-w","article-title":"Elevated serum thyroid stimulating immunoglobulin linked to failure of first-line intravenous methylprednisolone monotherapy in moderate-to-severe thyroid eye disease","volume":"38","author":"Zloto","year":"2024","journal-title":"Eye"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.788228","article-title":"Mycophenolate mofetil (CellCept\u00ae) in combination with low dose prednisolone in moderate to severe Graves\u2019 orbitopathy","volume":"9","author":"Rajabi","year":"2022","journal-title":"Front Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0420.2002.800316.x","article-title":"High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy","volume":"80","author":"Kauppinen-M\u00e4kelin","year":"2002","journal-title":"Acta Ophthalmol Scand"},{"key":"B105","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1530\/acta.0.1220008","article-title":"Azathioprine in the treatment of thyroid-associated ophthalmopathy","volume":"122","author":"Perros","year":"1990","journal-title":"Acta Endocrinol (Copenh)"},{"key":"B106","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S2213-8587(18)30021-4","article-title":"Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 \u00d7 2 factorial, double-blind, randomised controlled trial","volume":"6","author":"Rajendram","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1168936","article-title":"Azathioprine as an adjuvant therapy in severe Graves' disease: a randomized controlled open-label clinical trial","volume":"14","author":"Allam","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198911163212002","article-title":"Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy","volume":"321","author":"Prummel","year":"1989","journal-title":"N Engl J Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0315-9","article-title":"Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy","volume":"33","author":"Strianese","year":"2019","journal-title":"Eye (Lond)"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpor.2016.02.001","article-title":"Radiotherapy for Graves\u2019 disease. The possible role of low-dose radiotherapy","volume":"21","author":"Arenas","year":"2016","journal-title":"Rep Pract Oncol Radiother J Gt Cancer Cent Poznan Pol Soc Radiat Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12688","article-title":"A 2013 European survey of clinical practice patterns in the management of Graves\u2019 disease","volume":"84","author":"Bartalena","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.16535","article-title":"Management of Graves disease: a review","volume":"314","author":"Burch","year":"2015","journal-title":"JAMA"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz013","article-title":"A novel anti-CD40 monoclonal antibody, iscalimab, for control of Graves hyperthyroidism-a proof-of-concept trial","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211028653","article-title":"10 years of belimumab experience: What have we learnt","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"B115","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cca.2016.09.004","article-title":"Serum BAFF and thyroid autoantibodies in autoimmune thyroid disease","volume":"462","author":"Lin","year":"2016","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0507","article-title":"Treatment of autoimmune hyperthyroidism in a murine model of Graves\u2019 disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology","volume":"147","author":"Gilbert","year":"2006","journal-title":"Endocrinology"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1210\/en.2018-00306","article-title":"Immunotherapy with apitopes blocks the immune response to TSH receptor in HLA-DR transgenic mice","volume":"159","author":"Jansson","year":"2018","journal-title":"Endocrinology"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0036","article-title":"Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves\u2019 hyperthyroidism: a phase I study","volume":"29","author":"Pearce","year":"2019","journal-title":"Thyroid"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01287-y","article-title":"Teprotumumab: First approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"B120","unstructured":"TEPEZZA\u00ae (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE | Amgen Inc"},{"key":"B121","unstructured":"MHRA approves teprotumumab as the first UK treatment for adults with moderate to severe Thyroid Eye Disease (TED). GOVUK"},{"key":"B122","unstructured":"Tepezza | European Medicines Agency (EMA)\n          \n          \n          2025"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"key":"B126","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002867","article-title":"Clinical and radiologic predictors of response to teprotumumab: A 3D volumetric analysis of 35 patients","volume":"41","author":"Ugradar","year":"2025","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101111","article-title":"Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study","volume":"23","author":"Sears","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.09.89","article-title":"Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor","volume":"1","author":"Mulvihill","year":"2009","journal-title":"Future Med Chem"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2585616","article-title":"Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease","volume":"17","author":"Kaplan","year":"2025","journal-title":"mAbs"},{"key":"B131","unstructured":"Sling therapeutics"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2010.03831.x","article-title":"Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample","volume":"73","author":"Evans","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14681","article-title":"TSH receptor specific monoclonal autoantibody K1-70TM targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy-results from a phase I clinical trial","volume":"96","author":"Furmaniak","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B134","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1507\/endocrj.EJ25-0043","article-title":"Safety, pharmacokinetics, and potential benefits of TSH-receptor-specific monoclonal autoantibody K1-70TM in Japanese Graves' disease patients: results of a phase 1 trial","volume":"72","author":"Noh","year":"2025","journal-title":"Endocr J"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0694","article-title":"Thyrotropin receptor antagonism by a novel small molecule: Preclinical in vitro observations","volume":"33","author":"Kahaly","year":"2023","journal-title":"Thyroid"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqaf037","article-title":"Inhibition of TSH receptor expression by a cyclotriazadisulfonamide as a potential treatment of Graves hyperthyroidism","volume":"166","author":"Krieger","year":"2025","journal-title":"Endocrinology"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgag010","article-title":"Graves' disease: a new era of pathophysiology-guided therapeutics","volume":"111","author":"Stan","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2023.1295902","article-title":"Emerging therapies in the medical management of thyroid eye disease","volume":"3","author":"Kamboj","year":"2023","journal-title":"Front Ophthalmol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad381","article-title":"Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease","volume":"108","author":"Kahaly","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B140","unstructured":"A single-arm, open-label, prospective phase II study to evaluate the efficacy and safety of SHR-1314 by subcutaneous injection in active moderate to severe Graves\u2019 orbitopathy patients\n          \n          \n          \n          2024"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1177\/11795514261426446","article-title":"Pharmacologic therapies for active moderate-to-severe TED: A comprehensive systematic review","volume":"19","author":"Builes-Monta\u00f1o","year":"2026","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.12.012","article-title":"Management aspects of medical therapy in Graves disease","volume":"31","author":"Shah","year":"2025","journal-title":"Endocr Pract"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae472","article-title":"Effects of low-dose methotrexate with methimazole in patients with Graves' disease: Results of a randomized clinical trial","volume":"110","author":"Xie","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00238-2","article-title":"Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial","volume":"9","author":"Lanzolla","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0420.2002.800316.x","article-title":"High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy","volume":"80","author":"Kauppinen-M\u00e4kelin","year":"2002","journal-title":"Acta Ophthalmol Scand"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.6284","article-title":"Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease: A meta-analysis and matching-adjusted indirect comparison","volume":"140","author":"Douglas","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf227","article-title":"Long-term tocilizumab therapy in patients with corticosteroid-resistant active moderate-to-severe thyroid eye disease","volume":"193","author":"Dalmas","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.17925\/EE.2025.21.2.2","article-title":"Advancing the therapeutic frontier in thyroid eye disease","volume":"21","author":"Mohammadi","year":"2025","journal-title":"touchREV Endocrinol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-025-04197-z","article-title":"Horizon scanning from panel discussions at the EUGOGO Global TED Forum 2025 London","volume":"40","author":"Lee","year":"2026","journal-title":"Eye (Lond)"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.4103\/IJO.IJO_1035_24","article-title":"Thyroid-stimulating immunoglobulins as a reliable predictive blood test for thyroid eye disease","volume":"74","author":"Madgar","year":"2026","journal-title":"Indian J Ophthalmol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1707049","article-title":"N-phenethylacetamide, diaminopimelic acid, and Gly-Val as high-performance serum biomarkers for diagnosing untreated Graves' disease: an LC-MS-based metabolomics study","volume":"16","author":"Fang","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B152","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40246-025-00860-4","article-title":"Integrative transcriptomic profiling and machine learning reveal hypoxia-associated molecular signatures for precision diagnosis in thyroid eye disease","volume":"19","author":"Qian","year":"2025","journal-title":"Hum Genomics"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2026.04.019","article-title":"Noninvasive biomarkers for Graves' orbitopathy: Clinical relevance of circulating PAI-1, TGF-\u03b2 and IGF-1R","volume":"26","author":"Leszczy\u0144ska","year":"2026","journal-title":"Clin Ther"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1762376","article-title":"Extracellular vesicles in Graves' disease and Graves' orbitopathy: immunoregulatory mechanisms, biomarkers, and therapeutic potentials","volume":"17","author":"Chen","year":"2026","journal-title":"Front Immunol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15041428","article-title":"Nanoparticles in thyroid autoimmunity: Diagnostic and therapeutic applications","volume":"15","author":"Elia","year":"2026","journal-title":"J Clin Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1778702","article-title":"Vitamin D dynamics predict treatment response to intravenous glucocorticoids in thyroid-associated ophthalmopathy: a retrospective cohort study","volume":"17","author":"Wang","year":"2026","journal-title":"Front Immunol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-026-02913-4","article-title":"Serum free fatty acid profiles as novel biomarkers for disease activity in Graves' orbitopathy","author":"Yang","year":"2026","journal-title":"J Endocrinol Invest"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2026.110901","article-title":"Predictive value of tear lipidomics biomarkers for TAO activity and relationship with clinical characteristics","volume":"265","author":"Wang","year":"2026","journal-title":"Exp Eye Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-25-0363","article-title":"What has changed in thyroid eye disease in the last five years (2020-2025)","volume":"15","author":"Salvi","year":"2026","journal-title":"Eur Thyroid J"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0189","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"11","author":"Burch","year":"2022","journal-title":"Eur Thyroid J"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-026-01326-z","article-title":"Management of thyroid eye disease: a comparison between three recent clinical guidelines","volume":"15","author":"Lei","year":"2026","journal-title":"Ophthalmol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1800029\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:00:49Z","timestamp":1786608049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1800029\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":161,"alternative-id":["10.3389\/fimmu.2026.1800029"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1800029","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"1800029"}}